Urología

2024

1. Development of prediction models based on risk scores for clinically significant prostate cancer on MRI/TRUS fusion biopsy

   Urologic Oncology: Seminars and Original Investigations

2. Erratum to “P003 – The added value of systematic biopsy to targeted biopsy and selection of clinical variables in patients with PIRADS ≥ 3 lesions” [Eur. Urol. Open Sci. 57(Supplement 1) (2023) S19] (European Urology Open Science (2023) 57(S1) (S1–S380), (S2666168323X00160), (10.1016/S2666-1683(23)01310-1))

   European Urology Open Science

3. Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients

   International Journal of Molecular Sciences, Vol. 25, Núm. 13

4. MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics

   Cardiovascular Diabetology, Vol. 23, Núm. 1

5. Predicting Survival of Metastatic Clear Cell Renal Cell Cancer Treated with VEGFR-TKI-Based Sequential Therapy

   Cancers, Vol. 16, Núm. 16

6. Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study

   Actas Urologicas Espanolas, Vol. 48, Núm. 3, pp. 228-237

7. Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial

   Nature Medicine

8. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy

   International Journal of Molecular Sciences, Vol. 25, Núm. 3

9. Why is it necessary to produce a BCG strain in Spain?

   Actas Urologicas Espanolas